KAPA Biosystems

Kapa Biosystems was founded in 2006 to develop next-generation, molecular engineering technologies. Our directed evolution technology platform is currently being used to optimize enzymes for DNA amplification and molecular diagnostic applications.

The majority of biomedical and research applications were designed around a small subset of native enzymes. The limitations of these methods are often the result of constraints due to enzyme structure or function.Post-genomic technologies are enabling an era of molecular design that allows enzymes to be tailored to suit specific application requirements.

The Kapa Biosystems management team combines a strong balance of scientific and commercial expertise. Our world-class team of scientists is lead by Chief Scientific Officer, Paul McEwan, who has over 10 years of experience developing breakthrough biochemistry and instrumentation in the field of high-throughput genomics including: inventing technologies and automation for the Human Genome Project at the Whitehead Institute Center for Genomic Research leading to the co-founding of genomics companies Agencourt Bioscience and Agencourt Personal Genomics.

Kapa Biosystems is now leveraging the recent advances in genomics, proteomics, and synthetic biology for advanced protein engineering.